Product Description
SSR150106 is a very potent, non-peptidic, orally active inhibitor of the synthesis of pro-inflammatory cytokines (mainly TNF-_) and various chemokines (mainly MCP-1). SSR150106 was investigated for the treatment of rheumatoid arthritis. SSR150106 administered by oral route inhibited TNF-_, IFN-_, MCP-1, MIP-1_ and MIP-1_ production, and doses inhibiting 50% of their synthesis were in the range of 3-31 _g/kg. (Sourced from: https://ncats.nih.gov/files/SSR150106.pdf)
Mechanisms of Action: TNF Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Inflammation|Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACCORD-RA | P2 |
Completed |
Arthritis, Rheumatoid|Inflammation |
2008-06-01 |